Clinical study of Cisplatin Injection and Bevacizumab Injection joint irinotecan injection in the treatment of advanced stage of advanced breast cancer
Objective To investigate the efficacy and safety of bevacizumab in combination with Cisplatin Injection and irinotecan in patients with advanced second-line treatment of advanced breast cancer. Methods 60 cases of advanced a cancer patients who failed the treatment of first-line fluorouracil combined with oxaliplatin were divided into the experimental group and the control group by random control method, each group was 30 cases. The control group was given intravenous infusion of Cisplatin Injection 30 mg/m2 at second days, 15 min infusion, and intravenous infusion of irinotecan 300 mg/m2 on the same day, and instillation of 120 min. The experimental group in the first day on the basis of the control group, given intravenous infusion of bevacizumab 7.5 mg/kg plus saline 100 mL, intravenous infusion 90 min. Two groups of patients were 21d for a cycle, two cycles were treated. The clinical efficacy, progression free survival (PFS), overall survival (OS) and toxicity of the drug were compared between the experimental group and the control group in the treatment of advanced advanced breast cancer. Results The experimental groups of disease progression (PD) was 30.00%, the control group PD was 56.67%, the difference was statistically significant (P<0.05); objective remission rate of the experimental group (ORR) was 40.00%, the control group ORR was 16.67%, the difference was statistically significant (P<0.05); experimental group, the disease control rate (DCR 70%), the control group DCR was 43.33%, the difference was statistically significant (P<0.05); OS in the experimental group was 14 months (95% CI:8.7-17.9 ), OS in control group was 11 months (95% CI:5.1-13.9), the difference was statistically significant (P<0.05);in PFS of the experimental group was 8 months (95% CI:6.5-8.2), PFS in control group was 5 months (95% CI:4.3-7.2), the difference was statistically significant (P<0.05); the experimental group and the control group were myelosuppression, nausea and vomiting, and fatigue were abnormal obviously, to I - II The main level of toxicity, including granulocyte in experimental group decreased I-II adverse reaction rate was higher than the control group, the difference was statistically significant (46.67% vs. 20%, P=0.028); the incidence of postoperative nausea and vomiting in the experimental group I-II adverse reaction rate was higher than the control group, the difference was statistically significant (43.33% vs. 16.67%, P=0.024). Conclusion Bevacizumab and irinotecan combined with Cisplatin Injection can improve ORR and DCR in patients with irinotecan in patients with advanced scheme for second-line treatment of advanced breast cancer, prolonged PFS and OS, although have certain adverse drug reactions but acceptable.
bevacizumabCisplatin Injectionirinotecanadvanced breast cancer
NETL
NSTL
万方数据
维普
